文献速递湿疹皮炎与荨麻疹

Lebrikizumab治疗中重度特应性皮炎的疗效与安全性:两项随机双盲安慰剂对照III期试验的52周结果

Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials.
PubMed 文献 · Br J Dermatol · 2023-01-01

两项III期试验评估Lebrikizumab单药治疗青少年和成人中重度特应性皮炎52周的疗效与安全性。16周诱导期应答者再随机接受Q2W、Q4W或安慰剂,52周时IGA 0/1应答维持率分别为71.2%、76.9%和47.9%,EASI 75维持率分别为78.4%、81.7%和66.4%。

要点

  • 16周诱导期应答者再随机后,Q2W和Q4W维持IGA 0/1应答相似。
  • 52周时Q2W和Q4W的EASI 75维持率均高于安慰剂撤药组。
  • Lebrikizumab治疗患者中63.0%报告治疗中出现的不良事件,其中93.1%为轻中度。

核心结论

  • 经过16周Lebrikizumab Q2W诱导期后,Q2W和Q4W维持治疗对中重度特应性皮炎体征和症状的改善相似,安全性特征与既往发表数据一致。

研究设计与样本

  • 两项随机双盲安慰剂对照III期试验ADvocate1(NCT04146363)和ADvocate2(NCT04178967),评估Lebrikizumab单药治疗青少年和成人中重度特应性皮炎52周的疗效与安全性。
  • 16周诱导期接受Lebrikizumab 250 mg Q2W治疗应答的患者按2:2:1再随机接受Lebrikizumab Q2W、Lebrikizumab 250 mg Q4W或安慰剂Q2W(Lebrikizumab撤药)额外36周。
  • 16周应答定义为达到EASI 75或IGA 0或1且改善≥2分且未使用救援药物。
  • 采用多重插补处理缺失数据,维持期允许间歇使用局部治疗。

主要发现

  • 52周时,IGA 0或1且改善≥2分的维持率:Lebrikizumab Q2W组71.2%,Q4W组76.9%,Lebrikizumab撤药组47.9%。
  • 52周时,EASI 75维持率:Lebrikizumab Q2W组78.4%,Q4W组81.7%,Lebrikizumab撤药组66.4%。
  • 各治疗组中使用任何救援治疗的患者比例分别为14.0%(ADvocate1)和16.4%(ADvocate2)。
  • 在ADvocate1和ADvocate2的诱导期和维持期合并期间,63.0%的Lebrikizumab治疗患者报告任何治疗中出现的不良事件,其中大多数事件(93.1%)严重程度为轻或中度。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Lebrikizumab is a novel, high-affinity monoclonal antibody that selectively binds to interleukin (IL)-13. OBJECTIVES: To evaluate the efficacy and safety of lebrikizumab monotherapy in adolescent and adult patients with moderate-to-severe atopic dermatitis (AD) over 52 weeks of treatment in ADvocate1 (NCT04146363) and ADvocate2 (NCT04178967). METHODS: Patients who responded to lebrikizumab 250 mg every 2 weeks (Q2W) at the end of the 16-week induction period were re-randomized 2 : 2 : 1 to receive lebrikizumab Q2W, lebrikizumab 250 mg every 4 weeks (Q4W) or placebo Q2W (lebrikizumab withdrawal) for 36 additional weeks. Response at week 16 was defined as achieving a 75% reduction in Eczema Area Severity Index (EASI 75) or an Investigator's Global Assessment (IGA) of 0 or 1, with a ≥ 2-point improvement and no rescue medication use. Multiple imputation was used to handle missing data. Intermittent use of topical therapy was permitted during the maintenance period. RESULTS: After 52 weeks, an IGA of 0 or 1 with a ≥ 2 point improvement was maintained by 71.2% of patients treated with lebrikizumab Q2W, 76.9% of patients treated with lebrikizumab Q4W and 47.9% of patients in the lebrikizumab withdrawal arm. EASI 75 was maintained by 78.4% of patients treated with lebrikizumab Q2W, 81.7% of patients treated with lebrikizumab Q4W and 66.4% of patients in the lebrikizumab withdrawal arm at week 52. Across treatment arms, proportions of patients using any rescue therapy were 14.0% (ADvocate1) and 16.4% (ADvocate2). During the combined induction and maintenance periods of ADvocate1 and ADvocate2, 63.0% of lebrikizumab-treated patients reported any treatment emergent adverse event, with most events (93.1%) being mild or moderate in severity. CONCLUSIONS: After a 16-week induction period with lebrikizumab Q2W, lebrikizumab Q2W and Q4W maintained similar improvement of the signs and symptoms of moderate-to-severe AD, with a safety profile consistent with previously published data.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Blauvelt A, Thyssen JP, Guttman-Yassky E, et al. Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials. Br J Dermatol. 2023. PMID: 36994947. doi:10.1093/bjd/ljad022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。